Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates

Humphries, Romney M.; Hindler, Janet A.; Wong-Beringer, Annie; Miller, Samuel D.

doi:10.1128/aac.01858-17

Cited by 73 publications

(52 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While both tazobactam and avibactam inhibit serine beta-lactamase, tazobactam irreversibly binds to the active site of serine beta-lactamases. In addition, avibactam not only inhibits ESBLs, but also effectively inhibits class A carbapenemases such as AmpC beta-lactamases and Klebsiella pneumoniae carbapenemase (KPC) [7,14,15] . Avibactam has in vitro activity against Ambler class A, C, and some class D serine betalactamases, but not against metallo-beta-lactamases [1,4] .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Investigation of Ceftalozan / tazobactam and Ceftazidim / avibaktam invitro activity against Karbapenemaz producing Pseudomonas aeruginosa strains

Aydemir¹,

Terzi²,

Köroğlu³

et al. 2019

mjima

View full text Add to dashboard Cite

The emergence of multidrug-resistant (MDR) and extensively drug-resistant strains of Pseudomonas aeruginosa in recent years has become a major issue due to treatment difficulties as well as high morbidity and mortality rates. Treatment options for infections caused by these microorganisms are very limited. Ceftolozane/tazobactam (C/T) and ceftazidime/avibactam (CZA) are recently developed cephalosporin/betalactamase inhibitor combinations for the treatment of infections caused by MDR P. aeruginosa strains. The aim of this study was to investigate the in vitro efficacy of C/T and CZA against MDR P. aeruginosa strains and to compare the in vitro efficacy of these two drugs. Materials and Methods: Thirty-two MDR P. aeruginosa isolates were included in the study. Identification and antimicrobial susceptibilities of the strains were performed using a VITEK 2® automated system. The efficacy of CZA and C/T was determined by the gradient strip test (Liofilchem MIC strip test, Italy). Modified carbapenemase inactivation method was used to detect carbapenemase production in all strains. Results: Rates of antibiotic resistance in the isolates were 78% for amikacin, 96.8% for levofloxacin, 90.6% for ciprofloxacin, 71.8% for gentamicin, and 78% for netilmicin. Ceftazidime/avibactam resistance was detected in 7 (21.8%) of the isolates and C/T resistance in 10 (31.2%). All strains with resistance to CZA also had resistance to C/T. Three strains were resistant to C/T but susceptible to CZA. Carbapenemase production was positive in all strains. Conclusion: The results of this study indicate that CZA and C/T may be an alternative treatment for some of the carbapenem-resistant P. aeruginosa infections. Further in vitro and in vivo studies are needed to evaluate the effectiveness of these new treatment options against the increasing threat of MDR P. aeruginosa.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Although the efficacy of CZA and C/T against P. aeruginosa isolates has been adequately demonstrated, there has not been enough research investigating their efficacy against MDR P. aeruginosa infections or comparing their efficacy [5][6][7] . Our review of the literature yielded no studies on this subject conducted in Turkey.…”

Section: Introductionmentioning

confidence: 99%

Investigation of Ceftalozan / tazobactam and Ceftazidim / avibaktam invitro activity against Karbapenemaz producing Pseudomonas aeruginosa strains

Aydemir¹,

Terzi²,

Köroğlu³

et al. 2019

mjima

View full text Add to dashboard Cite

show abstract

“…This study highlights the critical importance of antimicrobial susceptibility testing (AST) of C-T and other new agents, particularly where it is known that not all isolates are susceptible. In a recent study of 309 P. aeruginosa isolates resistant to one or more antipseudomonal beta-lactams, the clinical scenario in which C-T is most likely to be considered for therapy, 73.4% were susceptible, 6.1% were intermediate, and 20.5% were resistant (10). Local testing of C-T is desirable, as the turnaround time to results when reference laboratories are used may be prolonged.…”

Section: Discussionmentioning

confidence: 99%

Performance of Ceftolozane-Tazobactam Etest, MIC Test Strips, and Disk Diffusion Compared to Reference Broth Microdilution for β-Lactam-Resistant Pseudomonas aeruginosa Isolates

et al. 2018

Self Cite

View full text Add to dashboard Cite

The performance characteristics of the ceftolozane-tazobactam (C-T) Etest (bioMérieux, Marcy l'Etoile, France), MIC test strips (MTS; Liofilchem, Italy), and disk diffusion (Hardy, Santa Ana, CA) were evaluated for a collection of 308 beta-lactam-resistant isolates of recovered from three institutions in Los Angeles, CA. Reference testing was performed by the reference broth microdilution (rBMD) method. MIC and disk results were interpreted using Clinical and Laboratory Standards Institute breakpoints. Overall, 72.5% of the isolates were susceptible to C-T by rBMD. Etest and disk diffusion demonstrated acceptable performance, whereas MTS yielded a greater than acceptable percentage of minor errors. Categorical agreement was 96.8% for Etest, 87.0% for MTS, and 92.9% for disk diffusion. No very major errors were observed by any test, and no major errors (ME) were observed by Etest or disk diffusion. Two ME (0.9% of susceptible isolates) were observed by MTS. The incidence of minor errors was 3.2%, 12.3%, and 7.1% for Etest, MTS, and disk diffusion, respectively. Essential agreement (EA) for Etest was excellent, at 97.7%, whereas the MICs obtained by MTS tended to be 1 to 2 dilutions higher than those obtained by rBMD, with an EA of 87.0%.

show abstract

“…1024-fold compared with ceftazidime alone. Additionally, the inclusion of this β-lactamase inhibitor reduces P. aeruginosa ceftazidime MICs by approximately 4-fold (74)(75)(76). The FDA-approved indications for use of ceftazidime-avibactam include complicated UTI and complicated intra-abdominal infections in conjunction with metronidazole (77).…”

Section: Ceftazidime-avibactammentioning

confidence: 99%

New Bugs and New Drugs: Updates in Clinical Microbiology

Lainhart

Yarbrough

Jean

2018

The Journal of Applied Laboratory Medicine

View full text Add to dashboard Cite

Background:The landscape of clinical microbiology laboratories is changing. As new technologies are introduced, we are better able to detect and identify pathogens and to recognize and characterize emerging antimicrobial resistance mechanisms. Content: In this review, a selected cross-section of current hot topics in clinical microbiology is discussed. These topics include (a) diagnostics for urinary tract and sexually transmitted infections; (b) phenotypic and genotypic methods of detecting carbapenem resistance and discussion of newly approved anti-infective agents for these multi-drug resistant organisms; and (c) the significance, epidemiology, and identification of the emerging pathogens Mycobacterium chimaera and Candida auris. Summary: Communication between clinical microbiologists and their clinical colleagues is imperative to convey the significance of emerging pathogens and resistance determinants, as well as the performance characteristics of new diagnostic methods. Additionally, as antimicrobial resistance is surging, it is important to comprehensively evaluate the resistance profiles of clinical isolates to facilitate antimicrobial stewardship and inform infection prevention measures. Although antimicrobial resistance is a global public health crisis, it is encouraging that new anti-infective agents are in the pipeline and being approved for use in patients. IMPACT STATEMENTThis review focuses on a cross-section of hot topics in clinical microbiology, including urinary tract and sexually transmitted infections and antimicrobial resistance determinants. As diagnostic methods in clinical microbiology result in enhanced identification of pathogens and antimicrobial resistance determinants, our understanding of the clinical relevance and impact of emerging infections is evolving.In this review, selected new technologies and assays are discussed, in addition to key emerging pathogens of public health importance and newly approved antimicrobial agents.

show abstract

Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates

Cited by 73 publications

References 15 publications

Investigation of Ceftalozan / tazobactam and Ceftazidim / avibaktam invitro activity against Karbapenemaz producing Pseudomonas aeruginosa strains

Investigation of Ceftalozan / tazobactam and Ceftazidim / avibaktam invitro activity against Karbapenemaz producing Pseudomonas aeruginosa strains

Performance of Ceftolozane-Tazobactam Etest, MIC Test Strips, and Disk Diffusion Compared to Reference Broth Microdilution for β-Lactam-Resistant Pseudomonas aeruginosa Isolates

New Bugs and New Drugs: Updates in Clinical Microbiology

Contact Info

Product

Resources

About